In vivo efficacy of anidulafungin and caspofungin against Candida glabrata and association with in vitro potency in the presence of sera.
about
Antifungal Susceptibility in Serum and Virulence Determinants of Candida Bloodstream Isolates from Hong KongSusceptibility of Pneumocystis to echinocandins in suspension and biofilm culturesMicafungin in the treatment of invasive candidiasis and invasive aspergillosisOccidiofungin's chemical stability and in vitro potency against Candida species.Comparative effects of micafungin, caspofungin, and anidulafungin against a difficult-to-treat fungal opportunistic pathogen, Candida glabrata.Dose escalation studies with caspofungin against Candida glabrata.In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model.The novel arylamidine T-2307 demonstrates in vitro and in vivo activity against echinocandin-resistant Candida glabrataThe echinocandin micafungin: a review of the pharmacology, spectrum of activity, clinical efficacy and safety.In vivo pharmacodynamic target investigation for micafungin against Candida albicans and C. glabrata in a neutropenic murine candidiasis model.Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection.Micafungin for the prophylaxis and treatment of Candida infections.Pharmacology and antifungal properties of anidulafungin, a new echinocandin.Current perspectives on echinocandin class drugs.A clinical review of echinocandins in pediatric patients.Echinocandin pharmacodynamics: review and clinical implications.Preclinical Pharmacokinetics and Pharmacodynamic Target of SCY-078, a First-in-Class Orally Active Antifungal Glucan Synthesis Inhibitor, in Murine Models of Disseminated Candidiasis.Pharmacokinetics, antifungal activity and clinical efficacy of anidulafungin in the treatment of fungal infections.Echinocandins: are they all the same?Echinocandin resistance in Candida species: mechanisms of reduced susceptibility and therapeutic approaches.Invasive fungal infections in newborns and current management strategies.Echinocandin resistance, susceptibility testing and prophylaxis: implications for patient management.Mechanisms of echinocandin antifungal drug resistance.Echinocandins: The Expanding Antifungal Armamentarium.Echinocandins in antifungal pharmacotherapy.Caspofungin for the treatment of immunocompromised and severely ill children and neonates with invasive fungal infectionsEvaluation of the disk diffusion method compared to the microdilution method in susceptibility testing of anidulafungin against filamentous fungi.Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints.Caspofungin dose escalation for invasive candidiasis due to resistant Candida albicans.Improved detection of Candida sp. fks hot spot mutants by using the method of the CLSI M27-A3 document with the addition of bovine serum albumin.Increases in SLT2 expression and chitin content are associated with incomplete killing of Candida glabrata by caspofungin.Pyrosequencing to detect mutations in FKS1 that confer reduced echinocandin susceptibility in Candida albicans.Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint.Echinocandin susceptibility testing of Candida spp. Using EUCAST EDef 7.1 and CLSI M27-A3 standard procedures: analysis of the influence of bovine serum albumin supplementation, storage time, and drug lots.Activity of anidulafungin in a murine model of Candida krusei infection: evaluation of mortality and disease burden by quantitative tissue cultures and measurement of serum (1,3)-beta-D-glucan levels.Delivery of antifungal agents using bioactive and nonbioactive bone cements.Oral glucan synthase inhibitor SCY-078 is effective in an experimental murine model of invasive candidiasis caused by WT and echinocandin-resistant Candida glabrata.Natural Antimicrobial Peptides as Inspiration for Design of a New Generation Antifungal Compounds.Influence of serum on in vitro susceptibility testing of echinocandins for Candida parapsilosis and Candida guilliermondii.
P2860
Q28388030-C2118AD0-2208-4EFD-A1FF-053FC75A9ACBQ28477349-E7DFAD9D-3D08-4AE8-A8D5-564F860EDA47Q35026516-99DA202F-80F8-45CF-B9A0-084DE46B720EQ35689277-93CD9C60-CB8F-4399-9DAC-B68686D9DEA7Q35806170-4E4F3BD4-937B-41DA-80DE-6B41D833F3D6Q36376559-DB55D73A-6B0E-4DC0-A1C9-9938126BC860Q36425025-B58A5C90-6BD9-43E4-95D4-D57A5D1621BFQ36551326-D10A4621-0A4C-402C-8DA3-7C7E58D6C4E1Q36828156-0A6F59A1-C040-4B61-8F39-0ECEEE2F8A82Q36932989-2D2521F7-9609-4551-996E-26FC31EDD4DCQ36933000-2ED8B1B7-6BB9-4A51-82F3-8D928E8B6FE9Q37124868-2A5ED34E-9087-4F5D-A421-8DEAB15C5D35Q37359613-AEFF6F52-0B62-4FC3-B887-6FC456A14CC1Q37554055-43C0533A-B14E-4A99-827F-D9275E350B9EQ37653647-FF3E7415-679E-4F8E-81CE-9DA04822700AQ37718385-29125BA8-71DD-4E75-A396-1B0318664E9AQ37720794-75E708E6-9103-498A-8121-20F668500298Q37785979-C9184C91-156E-4552-B416-C440D47DDB04Q37974743-7396018B-D892-4D13-A989-172E217FAA90Q38027469-C8AB0E50-BF26-494E-A5CD-FDB3C8E80FC6Q38119554-C011FCFE-8D75-4FC3-A0B9-ADADBF4ECE1BQ38254290-7BCFAFDA-229A-4AC0-A5BF-763EB3AC057BQ38550402-95F39AEB-7971-49D8-A97C-CD033157AF2EQ38633102-E8687C10-C5D2-4B2D-A17F-16FB05635367Q39458862-D864EFD3-6EA9-4DD9-826C-809D1C534AD2Q39701953-74121FB4-8531-4EE6-98E7-9A08F4A3C91BQ41361550-AF661CF8-D9B3-43DE-8E3F-A6E8285C0D6CQ41787736-E74A893F-F678-4856-B4BF-BE10138534F8Q41990022-825B9ACC-32E6-4418-8572-30B9812CC60EQ42035300-1F940288-40D6-4178-BA1B-074F99E05AD0Q42119802-AF59A628-7918-4326-9B8B-3748219B8101Q42235292-D0822671-627C-4D65-A21D-DEA9C37DDE86Q42545839-1E36B659-B865-4BC7-BE16-74B8E8372581Q42706331-B9958184-8232-4A04-B204-A5702D4FBA1CQ43153532-11F68212-6A1E-41FD-A0AE-61FC5844E323Q43276349-4B669F54-132B-47C4-8EB9-FE4A9867F792Q47410811-0805C5EA-04B5-4560-BEC5-B12A2987DE39Q48163141-B3D46B5C-6EFE-4D26-AC11-64064CCCFBA1Q51027528-404046DC-F813-446D-BA51-E0A3F4139337
P2860
In vivo efficacy of anidulafungin and caspofungin against Candida glabrata and association with in vitro potency in the presence of sera.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
In vivo efficacy of anidulafun ...... tency in the presence of sera.
@en
In vivo efficacy of anidulafun ...... tency in the presence of sera.
@nl
type
label
In vivo efficacy of anidulafun ...... tency in the presence of sera.
@en
In vivo efficacy of anidulafun ...... tency in the presence of sera.
@nl
prefLabel
In vivo efficacy of anidulafun ...... tency in the presence of sera.
@en
In vivo efficacy of anidulafun ...... tency in the presence of sera.
@nl
P2093
P2860
P356
P1476
In vivo efficacy of anidulafun ...... tency in the presence of sera.
@en
P2093
Destiny Molina
John R Graybill
Laura K Najvar
Marcos Olivo
Rosie Bocanegra
P2860
P304
P356
10.1128/AAC.00105-07
P407
P577
2007-02-16T00:00:00Z